TW202112372A - 治療具有腎損害患者的Fabry氏病之方法 - Google Patents

治療具有腎損害患者的Fabry氏病之方法 Download PDF

Info

Publication number
TW202112372A
TW202112372A TW109119640A TW109119640A TW202112372A TW 202112372 A TW202112372 A TW 202112372A TW 109119640 A TW109119640 A TW 109119640A TW 109119640 A TW109119640 A TW 109119640A TW 202112372 A TW202112372 A TW 202112372A
Authority
TW
Taiwan
Prior art keywords
migalastat
patient
frequency
administration
days
Prior art date
Application number
TW109119640A
Other languages
English (en)
Chinese (zh)
Inventor
富蘭克林 強森
Original Assignee
美商阿米庫斯醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商阿米庫斯醫療股份有限公司 filed Critical 美商阿米庫斯醫療股份有限公司
Publication of TW202112372A publication Critical patent/TW202112372A/zh

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW109119640A 2019-06-11 2020-06-11 治療具有腎損害患者的Fabry氏病之方法 TW202112372A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859904P 2019-06-11 2019-06-11
US62/859,904 2019-06-11

Publications (1)

Publication Number Publication Date
TW202112372A true TW202112372A (zh) 2021-04-01

Family

ID=71950725

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109119640A TW202112372A (zh) 2019-06-11 2020-06-11 治療具有腎損害患者的Fabry氏病之方法

Country Status (16)

Country Link
US (1) US20220313670A1 (https=)
EP (1) EP3982962A1 (https=)
JP (2) JP7677910B2 (https=)
KR (1) KR20220019796A (https=)
CN (1) CN114423427A (https=)
AR (1) AR120055A1 (https=)
AU (2) AU2020291002A1 (https=)
BR (1) BR112021024886A2 (https=)
CA (1) CA3141226A1 (https=)
CL (1) CL2021003280A1 (https=)
EA (1) EA202290024A1 (https=)
IL (1) IL288677A (https=)
MX (1) MX2021015352A (https=)
PH (1) PH12021553102A1 (https=)
TW (1) TW202112372A (https=)
WO (1) WO2020252129A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
AR109103A1 (es) * 2016-07-19 2018-10-31 Amicus Therapeutics Inc Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EP3565583A4 (en) * 2017-01-05 2020-12-02 Protalix Ltd. TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE
PT4324522T (pt) * 2017-05-30 2026-03-13 Amicus Therapeutics Inc Métodos de tratamento de pacientes com fabry tendo insuficiência renal
AR111971A1 (es) * 2017-05-30 2019-09-04 Amicus Therapeutics Inc Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
CA3224537C (en) * 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE

Also Published As

Publication number Publication date
EA202290024A1 (ru) 2022-03-14
KR20220019796A (ko) 2022-02-17
EP3982962A1 (en) 2022-04-20
JP7677910B2 (ja) 2025-05-15
CN114423427A (zh) 2022-04-29
AU2020291002A1 (en) 2022-01-06
CA3141226A1 (en) 2020-12-17
BR112021024886A2 (pt) 2022-01-25
AU2026200618A1 (en) 2026-04-16
US20220313670A1 (en) 2022-10-06
JP2025131572A (ja) 2025-09-09
PH12021553102A1 (en) 2023-10-09
AR120055A1 (es) 2022-02-02
IL288677A (en) 2022-02-01
CL2021003280A1 (es) 2022-10-07
JP2022536687A (ja) 2022-08-18
MX2021015352A (es) 2022-04-06
WO2020252129A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US11786516B2 (en) Methods of treating Fabry patients having renal impairment
TW202112372A (zh) 治療具有腎損害患者的Fabry氏病之方法
TW202537622A (zh) 經典型Fabry氏病患者之治療
US20240293387A1 (en) Methods of Treating Fabry Disease in Pediatric Patients
TW202322814A (zh) 治療有腎損傷的法布里患者的方法
US20260076951A1 (en) Methods of treating fabry disease in patients having renal impairment
TW202423436A (zh) 改善米加司他之藥物動力學的方法
CN118488839A (zh) 改善米加司他的药代动力学的方法